Ohyashiki Kazuma
First Department of Internal Medicine (Hematology Division), Tokyo Medical University.
Nihon Rinsho. 2008 Mar;66(3):569-74.
For cancer treatment-related anemia, it is recommended to use erythropoietin or darbepoetin alpha by the National Comprehensive Cancer Network (NCCN). The guideline proposed the risk assessment for anemia, as well. The introduction of erythropoietin or darbepoetin alpha for anemia in treated cancer patients is based on the improvement of quality of life. For patients with myelodysplastic syndrome (MDS), those with 5q- anomaly is recommended to use lenalidomide and low-risk MDS patients without 5q- and serum erythropoietin of less than 500 mU/ml are recommended to treat with erythropoietin or darbepoetin alpha. These new agents are currently under clinical trials in Japan.
对于癌症治疗相关贫血，美国国立综合癌症网络（NCCN）建议使用促红细胞生成素或阿法达贝泊汀。该指南还提出了贫血的风险评估。在接受治疗的癌症患者中引入促红细胞生成素或阿法达贝泊汀治疗贫血是基于生活质量的改善。对于骨髓增生异常综合征（MDS）患者，建议有5q-异常的患者使用来那度胺，而对于无5q-且血清促红细胞生成素低于500 mU/ml的低风险MDS患者，建议使用促红细胞生成素或阿法达贝泊汀进行治疗。这些新药目前正在日本进行临床试验。
